About the Company
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EXEL News
Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth
Losing money on investments is something no shareholder enjoys, least of all institutional investors who saw their holdings ...
Exelixis (NASDAQ: EXEL)
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx ...
Exelixis Inc (EXEL) Stock: What the Analysts are Saying
Exelixis Inc (NASDAQ: EXEL) has a price-to-earnings ratio that is above its average at 35.26x. The stock has a 36-month beta value of 0.58. Opinions on the stock are mixed, with 5 analysts rating it ...
Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Exelixis' (NASDAQ:EXEL) stock is up by a considerable 16% over the past month. However, we decided to pay attention to the company's fundamentals which don't appear to give a clear sign about the ...
Exelixis director Garber Alan M sells shares worth over $460k
Exelixis, Inc. (NASDAQ:EXEL) director Garber Alan M has recently engaged in significant trading activity, according to a new SEC filing. On March 21, Garber sold 19,205 shares of the biotechnology ...
Buy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performance
JMP Securities analyst Silvan Tuerkcan has maintained their bullish stance on EXEL stock, giving a Buy rating on April 4. Silvan Tuerkcan has ...
Exelixis Stock (NASDAQ:EXEL), Quotes and News Summary
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Employer search : Exelixis Inc
For registered lobbyists, employment histories may be incomplete prior to 1998 because the Senate Office of Public Records does not make registrations and reports available electronically for those ...
Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Exelixis has seen strong revenue growth from its drug cabozantinib, but its net income has been inconsistent. The company is facing patent challenges from generics, with the potential for a ...
What Analysts Are Saying About Exelixis Stock
In the preceding three months, 4 analysts have released ratings for Exelixis EXEL, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...
Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Exelixis' (NASDAQ:EXEL) stock is up by a considerable 16% over the past month. However, we decided to pay attention to the company's fundamentals which don't appear to give a clear sign about the ...
Loading the latest forecasts...